Investigational drug · Phase 2
FC084CSA
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "FC084CSA"
First trial start
2024
Nov 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FC084CSA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FC084CSA" as an intervention, largest first.
- A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid TumorsRecruiting
FindCure Biosciences (ZhongShan) Co., Ltd.Industry
NCT06499350 · 33 participants (planned) · Start Nov 13, 2024 · Primary completion Dec 1, 2026
Drug: FC084CSA+Tislelizumab combination (dose escalation); RP2D of FC084CSA+Tislelizumab combination (dose expansion) · For: Advanced Malignant Solid Tumors
Sites: Shanghai, China
FindCure Biosciences (ZhongShan) Co., Ltd.Industry
NCT06231550 · 21 participants · Start Mar 1, 2023 · Primary completion Mar 18, 2025
Drug: FC084CSA tablets · For: Advanced Malignant Solid Tumors
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Malignant Solid Tumors
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- SCTB39GPhase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumors
- RCZY690Phase 21 trial
Rongchang Pharmaceuticals Co., Ltd. · Advanced Malignant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.